RTW Investments has agreed to back uro-oncology specialist UroGen Pharma with $75 million in upfront cash in return for tiered, future cash payments based on aggregate worldwide annual net product sales of UroGen products.
Founded by Roderick Wong in 2011, New York-based RTW operates both a venture strategy and hedge fund strategy totaling a combined $3.6 billion. Wong, an MD, is responsible for managing the firm’s investments focused on innovative drug development. Prior to forming RTW, he was a managing director and sole portfolio manager for the Davidson Kempner Healthcare Funds.
Continue Reading
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.
